Status:
ACTIVE_NOT_RECRUITING
Reference Values and Clinical Screening Test of Diffuse Noxious Inhibitory Controls (DNIC)
Lead Sponsor:
Université de Sherbrooke
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Centre for Research of CHUS (CRCHUS)
Conditions:
Chronic Pain
Eligibility:
All Genders
18-79 years
Brief Summary
Chronic pain (CP) is disabling for people triggering important costs for society. A deficit of diffuse noxious inhibitory controls (DNIC) is one of the CP mechanisms. DNICs are evaluated in research s...
Detailed Description
This study aims: 1. To establish baseline values of DNICs using CPM protocol 2. To identify the variables that will be integrated in the algorithm of the clinical screening test (clinical decision ru...
Eligibility Criteria
Inclusion
- 18-79 years old
- Able to provide consent
Exclusion
- cardiovascular disease (arrhythmia, cerebrovascular accident, infarction...)
- Raynaud syndrome
- severe psychiatric disease (dementia, schizophrenia, psychosis, major depression)
- injuries or loss sensitivity to their forearms or hands
- pregnant women or in post-partum period (\<1 year)
Key Trial Info
Start Date :
November 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
468 Patients enrolled
Trial Details
Trial ID
NCT03376867
Start Date
November 27 2017
End Date
December 30 2024
Last Update
February 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universite de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 5N4